CSTONE PHARMA-B (02616) granted a total of 15.7155 million share options and 8.055 million restricted share units.

CSTONE PHARMA-B(02616) announced that on January 23, 2026, the board of directors has resolved to grant a total of 15.7155 million share options to 96 option grantees under the employee share option scheme following the initial public offering. Of the total 15.7155 million share options granted to the option grantees, 7 million share options were granted to one director and 8.7155 million share options were granted to employees of the company (including senior management members). On January 23, 2026, the board of directors also resolved to grant a total of 8.055 million restricted share units to 88 restricted share unit grantees under the restricted share unit award scheme following the initial public offering. Of the total 8.055 million restricted share units granted to the restricted share unit grantees, 4.27 million restricted share units were granted to one director and 3.785 million restricted share units were granted to employees of the company (including senior management members).